The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Debiopharm Group; Roche; TFS
Travel, Accommodations, Expenses - Merck Serono; Roche
Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
 
Anas Gazzah
No Relationships to Disclose
 
Charles Ricordel
Honoraria - AstraZeneca
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Sophie Cousin
No Relationships to Disclose
 
Byoung Chul Cho
Stock and Other Ownership Interests - Bridgebio; Gencurix; Theravance
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - START
Stock and Other Ownership Interests - International Cancer Consultants; Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Abbvie; Amcure; AstraZeneca; Celgene; EUSA Pharma; Gerson Lehrman Group; Guidepoint Global; Janssen-Cilag; Nanobiotix; Novartis; Pfizer; PsiOxus Therapeutics; Roche/Genentech; Seagen; SERVIER
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; BeiGene; Novartis; START
Travel, Accommodations, Expenses - Roche/Genentech
Other Relationship - Investigational Therapeutics in Oncological Sciences
 
Tae Min Kim
Research Funding - AstraZeneca
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune; Bayer; Boryung; Novartis; Sanofi; Takeda; Voronoi Health Analytics
 
Carole Helissey
Honoraria - Astellas Pharma; Janssen; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Janssen; Roche; Sanofi
Expert Testimony - Astellas Pharma; Janssen; Roche; Sanofi
 
Jin-Soo Kim
Stock and Other Ownership Interests - Chong Kun Dang Pharmaceutical; DAEHWA Pharmaceutical
Honoraria - AstraZeneca; Boehringer Ingelheim; CJ Healthcare; DAEHWA Pharmaceutical; Lilly; Merck
Consulting or Advisory Role - CJ Healthcare; Lilly
Research Funding - Alpha Biopharma; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chong Kun Dang Pharmaceutical; CJ Healthcare; Hanmi; IL-Yang Pharm; Lilly; Merck; MSD; Novotech; Ono Pharmaceutical; Pfizer; Sanofi; Yuhan
Expert Testimony - CJ Healthcare
 
Maria Vieito
No Relationships to Disclose
 
Valentina Boni
Honoraria - IDEAYA Biosciences; Loxo
Consulting or Advisory Role - Guidepoint Global; OncoArt
Speakers' Bureau - Solti
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - START
 
Mustapha Chadjaa
Employment - Sanofi
 
Marie Hospitel
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
Patents, Royalties, Other Intellectual Property - Sanofi
 
Semra Yoruk
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
Patents, Royalties, Other Intellectual Property - Sanofi
 
Fabrice Barlesi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech